145 related articles for article (PubMed ID: 12214161)
21. [Acquired von Willebrand syndrome: a case series of nine patients and literature review].
Boissier E; Darnige L; Dougados J; Arlet JB; Dupeux S; Georgin-Lavialle S; Caron C; Tapon-Bretaudière J; Pouchot J; Ranque B
Rev Med Interne; 2014 Mar; 35(3):154-9. PubMed ID: 23746599
[TBL] [Abstract][Full Text] [Related]
22. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.
Mohri H
J Thromb Thrombolysis; 2003 Jun; 15(3):141-9. PubMed ID: 14739623
[TBL] [Abstract][Full Text] [Related]
23. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
Mannucci PM; Capoferri C; Canciani MT
Br J Haematol; 2004 Jul; 126(2):213-8. PubMed ID: 15238142
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
26. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
Rauch A; Legendre P; Christophe OD; Goudemand J; van Belle E; Vincentelli A; Denis CV; Susen S; Lenting PJ
Thromb Haemost; 2014 Nov; 112(5):1014-23. PubMed ID: 25030452
[TBL] [Abstract][Full Text] [Related]
27. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease.
van Genderen PJ; Michiels JJ; Bakker JJ; van 't Veer MB
Vox Sang; 1994; 67(1):14-7. PubMed ID: 7975445
[TBL] [Abstract][Full Text] [Related]
29. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Sucker C; Michiels JJ; Zotz RB
Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
[TBL] [Abstract][Full Text] [Related]
30. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.
Obert B; Tout H; Veyradier A; Fressinaud E; Meyer D; Girma JP
Thromb Haemost; 1999 Nov; 82(5):1382-5. PubMed ID: 10595622
[TBL] [Abstract][Full Text] [Related]
31. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress.
Yagi H; Konno M; Kinoshita S; Matsumoto M; Ishizashi H; Matsui T; Titani K; Fujimura Y
Br J Haematol; 2001 Dec; 115(4):991-7. PubMed ID: 11843838
[TBL] [Abstract][Full Text] [Related]
32. Autoantibody to von Willebrand factor in systemic lupus erythematosus.
Soff GA; Green D
J Lab Clin Med; 1993 Mar; 121(3):424-30. PubMed ID: 8445290
[TBL] [Abstract][Full Text] [Related]
33. IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome.
Howard CR; Lin TL; Cunningham MT; Lipe BC
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):631-3. PubMed ID: 24686099
[TBL] [Abstract][Full Text] [Related]
34. Ischaemia-reperfusion injury with Pringle's maneuver induces unusually large von Willebrand factor multimers after hepatectomy.
Yoshikawa T; Nomi T; Sakai K; Hayakawa M; Hokuto D; Matsuo Y; Sho M; Matsumoto M
Thromb Res; 2019 Nov; 183():20-27. PubMed ID: 31518960
[TBL] [Abstract][Full Text] [Related]
35. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.
Kubo M; Sakai K; Hayakawa M; Kashiwagi H; Yagi H; Seki Y; Hasegawa A; Tanaka H; Amano I; Tomiyama Y; Matsumoto M
J Thromb Haemost; 2022 Jul; 20(7):1589-1598. PubMed ID: 35352474
[TBL] [Abstract][Full Text] [Related]
36. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
Friederich PW; Wever PC; Briët E; Doorenbos CJ; Levi M
Am J Hematol; 2001 Apr; 66(4):292-4. PubMed ID: 11279642
[TBL] [Abstract][Full Text] [Related]
38. Management of acquired von Willebrand's syndrome in a patient requiring major surgery.
Maddox JM; Anderson JA; Plews D; Ludlam CA
Haemophilia; 2005 Nov; 11(6):633-7. PubMed ID: 16236115
[TBL] [Abstract][Full Text] [Related]
39. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.
Bergamaschini L; Mannucci PM; Federici AB; Coppola R; Guzzoni S; Agostoni A
J Lab Clin Med; 1995 Mar; 125(3):348-55. PubMed ID: 7897302
[TBL] [Abstract][Full Text] [Related]
40. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Tsai HM; Chandler WL; Sarode R; Hoffman R; Jelacic S; Habeeb RL; Watkins SL; Wong CS; Williams GD; Tarr PI
Pediatr Res; 2001 May; 49(5):653-9. PubMed ID: 11328948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
